Skip to main content

Advertisement

SpringerLink
Log in

Cutaneous adverse reactions to therapeutic monoclonal antibodies for cancer

  • Published:
Current Colorectal Cancer Reports

Abstract

Advances in molecular biology have led to the successful development of targeted monoclonal antibodies to several types of malignancies. By June 2007, nine therapeutic monoclonal antibodies had been approved by the US Food and Drug Administration to treat various human cancers. In general, the adverse reactions of these agents have been milder than their cytotoxic chemotherapy counterparts, but side effects do occur. Cutaneous adverse reactions to the first of these agents were rare, and primarily limited to infusion reactions, local inflammation at injection sites, and ill-defined transient eruptions. However, the use of monoclonal antibody therapy against the epidermal growth factor receptor-1 in gastrointestinal and head and neck cancer has been frequently associated with significant skin reactions. As the use of these agents becomes more widespread, the recognition and management of these skin reactions becomes an increasingly important part of patient care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. American Cancer Society: Monoclonal antibodies. http://www.cancer.org/docroot/ETO/content/ETO_1_4X_Monoclonal_Antibody_Therapy_Passive_Immunotherapy.asp. Accessed August 7, 2007.

  2. Li Y, Zhu Z: Monoclonal antibody-based therapeutics for leukemia. Expert Opin Biol Ther 2007, 7:319–330.

    Article  PubMed  CAS  Google Scholar 

  3. Winter JN: Defining the role of immunotherapy and radiotherapy in the treatment of low-grade lymphoma. Curr Opin Hematol 2007, 14:360–368.

    Article  PubMed  CAS  Google Scholar 

  4. McLaughlin P, Grillo-Lopez AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825–2833.

    PubMed  CAS  Google Scholar 

  5. Kimby E: Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005, 31:456–473.

    Article  PubMed  CAS  Google Scholar 

  6. Grillo-Lopez E, Hedrich M, Rashford M, Benyunes M: Rituximab: ongoing and future clinical developments. Semin Oncol 2002, 29(Suppl. 2):105–112.

    Article  PubMed  CAS  Google Scholar 

  7. Alinari L, Lapalombella, Andritsos L, et al.: Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene 2007, 26:3644–3653.

    Article  PubMed  CAS  Google Scholar 

  8. Sievers EL, Larson RA, Stadtmauer EA, et al.: Efficacy and safety of gemtuzumab ozogamacin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001, 19:3244–3254.

    PubMed  CAS  Google Scholar 

  9. Gordon LI, Witzig TE, Wiseman GA, et al.: Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin’s lymphoma. Semin Oncol 2002, 29(Suppl 2):87–92.

    Article  PubMed  CAS  Google Scholar 

  10. Mylotarg. In: Physicians’ Desk Reference, edn 61. Montville, NJ: Thompson PDR; 2007:3433.

  11. Ibritumomab: serious cutaneous reactions. Prescrire Int 2006, 15:139.

  12. Kaminski MS, Zelenetz AD, Press OW, et al.: Pivotal study of iodine I-131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 2001, 19:3918–3928.

    PubMed  CAS  Google Scholar 

  13. Press OW, Unger JM, Braziel RM, et al.: Phase II trial of CHOP chemotherapy followed by tositimomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin’s lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006, 24:4143–4149.

    Article  PubMed  CAS  Google Scholar 

  14. Hudis CA: Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med 2007, 357:39–51.

    Article  PubMed  CAS  Google Scholar 

  15. Nahta R, Esteva FJ: Trastuzumab: triumphs and tribulations. Oncogene 2007, 26:3637–3643.

    Article  PubMed  CAS  Google Scholar 

  16. Laux I, Jain A, Singh S, Agus DA: Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br J Cancer 2006, 94:85–92.

    Article  PubMed  CAS  Google Scholar 

  17. Herceptin. In: Physicians’ Desk Reference, edn 61. Montville, NJ: Thompson PDR; 2007:1236

  18. Pfeiffer P, Qvortrup C, Eriksen JG: Current role of antibody therapy in patients with metastatic colorectal cancer. Oncogene 2007, 26:3661–3678.

    Article  PubMed  CAS  Google Scholar 

  19. Gordon MS, Cunningham D: Managing patient treated with bevacizumab combination therapy. Oncology 2005, 69(Suppl 3):25–33.

    Article  Google Scholar 

  20. Gotlib V, Khaled S, Lapko I, et al.: Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and the relation to response. Anticancer Drugs 2006, 17:1227–1229.

    Article  PubMed  CAS  Google Scholar 

  21. Scappaticci FA, Fehrenbacher L, Cartwright T, et al.: Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005, 91:173–180.

    Article  PubMed  CAS  Google Scholar 

  22. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al.: Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21:60–65.

    Article  PubMed  CAS  Google Scholar 

  23. Saltz LB, Meropol NJ, Loehrer PJ, et al.: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor. J Clin Oncol 2004, 22:1201–1208.

    Article  PubMed  CAS  Google Scholar 

  24. Karamouzis MV, Grandis JR, Argiris A: Therapies directed against the epidermal growth factor in aerodigestive carcinomas. JAMA 2007, 298:70–82.

    Article  PubMed  CAS  Google Scholar 

  25. Cunninghan D, Humblet Y, Siena S, et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 2004, 351:337–345.

    Article  Google Scholar 

  26. Bonner JA, Harari PM, Giralt J, et al.: Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 2006, 354:567–578.

    Article  PubMed  CAS  Google Scholar 

  27. Saif MW, Kim R: Incidence and management of cutaneous toxicities associated with cetuximab. Expert Opin Drug Saf 2007, 6:175–182.

    Article  PubMed  CAS  Google Scholar 

  28. O’Neill BH, Allen RA, Spigel DR, et al.: High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 2007, 25:3644–3648.

    Article  Google Scholar 

  29. Budach W, Bolke E, Homey B: Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 2007, 357:514–515.

    Article  PubMed  CAS  Google Scholar 

  30. Perez-Soler R, Delord JP, Halpern A, et al.: HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005, 10:345–356.

    Article  PubMed  CAS  Google Scholar 

  31. Agero AL, Dusza SW, Benvenuto-Andrade C, et al.: Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006, 55:657–670.

    Article  PubMed  Google Scholar 

  32. Perez-Soler R, Saltz L: Cutaneous adverse effects with HER1-EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005, 23:5235–5246.

    Article  PubMed  Google Scholar 

  33. Van Cutsem E, Peeters M, Siena S, et al.: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25:1658–1664.

    Article  PubMed  Google Scholar 

  34. Giustri RM, Shastri KA, Cohen MH, et al.: FDA drug approval summary: panitumumab (Vectibix). Oncologist 2007, 12:577–583.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dermatology Service, Memorial Sloan-Kettering Cancer Center, 160 East 53rd Street, New York, NY, 10022, USA

    Patricia L. Myskowski

Authors
  1. Patricia L. Myskowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Allan C. Halpern
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patricia L. Myskowski.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Myskowski, P.L., Halpern, A.C. Cutaneous adverse reactions to therapeutic monoclonal antibodies for cancer. Curr colorectal cancer rep 5, 120–125 (2009). https://doi.org/10.1007/s11888-009-0018-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11888-009-0018-5

Keywords

Search

Navigation